Enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA), derived from Chinese hamster ovary (CHO) cells, was approved as registered treatment for patients with Pompe disease in 2006 (Myozyme, Genzyme Corporation). The gene discussed is GAA; the disease is Glycogen storage disease due to acid maltase deficiency.